<p>挪威銀行在第二季度購買了 Organon &amp; Co.（紐約證券交易所代碼：OGN - 免費報告）的新股份，根據該公司最近向美國證券交易委員會（SEC）披露的信息。該基金購買了 2,043,153 股公司股票，價值約為 19,778,000 美元。截至最近的 SEC 備案，挪威銀行持有 Organon &amp; Co.約 0.79% 的股份。</p>
<p>獲取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
<ul>
<li>道瓊斯最熱門的股票默克準備發佈第四季度財報</li>
</ul>
<p>其他對沖基金和機構投資者也對該公司的持倉進行了調整。Ransom Advisory Ltd 在第一季度購買了價值約 32,000 美元的 Organon &amp; Co.新股份。Hanson &amp; Doremus Investment Management 在第二季度購買了價值約 26,000 美元的 Organon &amp; Co.新股份。Hantz Financial Services Inc.在第二季度將其在 Organon &amp; Co.的持倉提高了 293.8%。Hantz Financial Services Inc.現在擁有 2,674 股公司股票，價值 26,000 美元，此前在該期間內又購買了 1,995 股。Brooklyn Investment Group 在第一季度將其在 Organon &amp; Co.的股份增加了 1,012.3%。Brooklyn Investment Group 現在擁有 3,070 股公司股票，價值 46,000 美元，此前在上個季度又購買了 2,794 股。最後，BI Asset Management Fondsmaeglerselskab A S 在第一季度購買了價值約 51,000 美元的 Organon &amp; Co.新股份。77.43% 的股票由機構投資者持有。</p>
<h2>分析師評級變動</h2>
<p>一些股票分析師最近對該股票發佈了報告。摩根士丹利將 Organon &amp; Co.的目標價格從 10.00 美元下調至 9.00 美元，並在 11 月 11 日的研究報告中對該公司給予了 “持平” 評級。摩根大通將 Organon &amp; Co.的目標價格從 14.00 美元下調至 12.00 美元，並在 11 月 11 日的研究報告中對該股票給予了 “減持” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Organon &amp; Co.的 “賣出（d+）” 評級。最後，Piper Sandler 將 Organon &amp; Co.的評級從 “增持” 下調至 “減持”，並設定了 5.00 美元的目標價格。在一位股票研究分析師的評級中，該股票獲得了強烈買入評級，一位給予了買入評級，兩位給予了持有評級，三位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價格為 12.50 美元。</p>
<ul>
<li>Lululemon Athletica 因進入標準普爾 500 指數而創下新高</li>
</ul>
<p><strong>獲取我們關於 OGN 的最新報告</strong></p>
<h2>Organon &amp; Co.股票上漲 2.3%</h2>
<p>Organon &amp; Co.的股票在週二以 7.30 美元開盤。該公司的 50 日移動平均價格為 8.22 美元，200 日移動平均價格為 9.21 美元。該公司的速動比率為 1.20，流動比率為 1.75，債務與股本比率為 9.69。Organon &amp; Co.的 12 個月低點為 6.18 美元，12 個月高點為 17.23 美元。該公司的市值為 19 億美元，市盈率為 3.80，市盈率/增長比率為 1.53，貝塔係數為 0.57。</p>
<p>Organon &amp; Co.（紐約證券交易所代碼：OGN - 獲取免費報告）最近在 11 月 10 日發佈了季度財報。該公司報告季度每股收益為 1.01 美元，超出市場共識預期的 0.93 美元，超出幅度為 0.08 美元。Organon &amp; Co.的股本回報率為 143.47%，淨利潤率為 7.95%。該公司在本季度的收入為 16 億美元，而市場共識預期為 15.7 億美元。在去年同期，該公司每股收益為 1.38 美元。整體來看，股票分析師預測 Organon &amp; Co.在當前年度的每股收益將達到 3.68 美元。</p>
<h2>Organon &amp; Co.股息公告</h2>
<p>該公司最近還宣佈了一項季度股息，將於 12 月 11 日支付。11 月 20 日的股東將獲得每股 0.02 美元的股息。這相當於年化股息 0.08 美元，股息收益率為 1.1%。該股息的除息日期為 11 月 20 日。Organon &amp; Co.目前的股息支付比率為 4.17%。</p>
<h2>關於 Organon &amp; Co.</h2>
<p>（免費報告）</p>
<p>Organon &amp; Co.是一家基於科學的全球製藥公司，通過一系列處方療法在女性健康、生物類似藥和成熟品牌領域開發和提供創新健康解決方案。該公司成立於 2020 年 3 月 11 日，總部位於新澤西州澤西市。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Organon &amp; Co。</li>
<li>異常交易量的股票：如何實時找到異常交易量的股票</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的影響</li>
<li>如何一步一步購買便宜股票</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>動盪市場中的資產配置策略</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Organon &amp; Co.嗎？</h2>
<p>在考慮投資 Organon &amp; Co.之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Organon &amp; Co.並不在名單上。</p>
<p>雖然 Organon &amp; Co.目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>挪威銀行在第二季度收購了 2,043,153 股 Organon & Co.的股票，價值 1978 萬美元。該股票的分析師評級不一，市場共識目標價為 12.50 美元。Organon & Co.報告第三季度每股收益為 1.01 美元，超出預期。公司宣佈季度股息為每股 0.02 美元，將於 12 月 11 日支付</p>

<p>Norges Bank purchased a new position in shares of Organon &amp; Co. (NYSE:OGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 2,043,153 shares of the company's stock, valued at approximately $19,778,000. Norges Bank owned about 0.79% of Organon &amp; Co. as of its most recent SEC filing.</p>
<div class="lb-trans"><p>挪威銀行在第二季度購買了 Organon &amp; Co.（紐約證券交易所代碼：OGN - 免費報告）的新股份，根據該公司最近向美國證券交易委員會（SEC）披露的信息。該基金購買了 2,043,153 股公司股票，價值約為 19,778,000 美元。截至最近的 SEC 備案，挪威銀行持有 Organon &amp; Co.約 0.79% 的股份。</p>
</div><p>Get <strong>Organon &amp; Co.</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
</div><ul>
<li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li>
</ul>
<div class="lb-trans"><ul>
<li>道瓊斯最熱門的股票默克準備發佈第四季度財報</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also made changes to their positions in the company. Ransom Advisory Ltd bought a new position in shares of Organon &amp; Co. during the first quarter worth approximately $32,000. Hanson &amp; Doremus Investment Management bought a new stake in shares of Organon &amp; Co. in the second quarter valued at approximately $26,000. Hantz Financial Services Inc. lifted its position in Organon &amp; Co. by 293.8% during the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company's stock worth $26,000 after purchasing an additional 1,995 shares during the period. Brooklyn Investment Group grew its stake in Organon &amp; Co. by 1,012.3% during the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company's stock worth $46,000 after buying an additional 2,794 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Organon &amp; Co. in the first quarter valued at approximately $51,000. 77.43% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他對沖基金和機構投資者也對該公司的持倉進行了調整。Ransom Advisory Ltd 在第一季度購買了價值約 32,000 美元的 Organon &amp; Co.新股份。Hanson &amp; Doremus Investment Management 在第二季度購買了價值約 26,000 美元的 Organon &amp; Co.新股份。Hantz Financial Services Inc.在第二季度將其在 Organon &amp; Co.的持倉提高了 293.8%。Hantz Financial Services Inc.現在擁有 2,674 股公司股票，價值 26,000 美元，此前在該期間內又購買了 1,995 股。Brooklyn Investment Group 在第一季度將其在 Organon &amp; Co.的股份增加了 1,012.3%。Brooklyn Investment Group 現在擁有 3,070 股公司股票，價值 46,000 美元，此前在上個季度又購買了 2,794 股。最後，BI Asset Management Fondsmaeglerselskab A S 在第一季度購買了價值約 51,000 美元的 Organon &amp; Co.新股份。77.43% 的股票由機構投資者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of equities analysts recently issued reports on the stock. Morgan Stanley lowered their price objective on shares of Organon &amp; Co. from $10.00 to $9.00 and set an &#34;equal weight&#34; rating for the company in a research report on Tuesday, November 11th. JPMorgan Chase &amp; Co. reduced their price objective on shares of Organon &amp; Co. from $14.00 to $12.00 and set an &#34;underweight&#34; rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings reiterated a &#34;sell (d+)&#34; rating on shares of Organon &amp; Co. in a research note on Wednesday, October 8th. Finally, Piper Sandler cut Organon &amp; Co. from an &#34;overweight&#34; rating to an &#34;underweight&#34; rating and set a $5.00 target price on the stock. in a report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $12.50.</p>
<div class="lb-trans"><p>一些股票分析師最近對該股票發佈了報告。摩根士丹利將 Organon &amp; Co.的目標價格從 10.00 美元下調至 9.00 美元，並在 11 月 11 日的研究報告中對該公司給予了 “持平” 評級。摩根大通將 Organon &amp; Co.的目標價格從 14.00 美元下調至 12.00 美元，並在 11 月 11 日的研究報告中對該股票給予了 “減持” 評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Organon &amp; Co.的 “賣出（d+）” 評級。最後，Piper Sandler 將 Organon &amp; Co.的評級從 “增持” 下調至 “減持”，並設定了 5.00 美元的目標價格。在一位股票研究分析師的評級中，該股票獲得了強烈買入評級，一位給予了買入評級，兩位給予了持有評級，三位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價格為 12.50 美元。</p>
</div><ul>
<li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li>
</ul>
<div class="lb-trans"><ul>
<li>Lululemon Athletica 因進入標準普爾 500 指數而創下新高</li>
</ul>
</div><p><strong>Get Our Latest Report on OGN</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 OGN 的最新報告</strong></p>
</div><h2>Organon &amp; Co. Stock Up 2.3%</h2>
<div class="lb-trans"><h2>Organon &amp; Co.股票上漲 2.3%</h2>
</div><p>Organon &amp; Co. stock opened at $7.30 on Tuesday. The firm has a 50 day moving average price of $8.22 and a 200-day moving average price of $9.21. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. Organon &amp; Co. has a twelve month low of $6.18 and a twelve month high of $17.23. The company has a market capitalization of $1.90 billion, a P/E ratio of 3.80, a P/E/G ratio of 1.53 and a beta of 0.57.</p>
<div class="lb-trans"><p>Organon &amp; Co.的股票在週二以 7.30 美元開盤。該公司的 50 日移動平均價格為 8.22 美元，200 日移動平均價格為 9.21 美元。該公司的速動比率為 1.20，流動比率為 1.75，債務與股本比率為 9.69。Organon &amp; Co.的 12 個月低點為 6.18 美元，12 個月高點為 17.23 美元。該公司的市值為 19 億美元，市盈率為 3.80，市盈率/增長比率為 1.53，貝塔係數為 0.57。</p>
</div><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.93 by $0.08. Organon &amp; Co. had a return on equity of 143.47% and a net margin of 7.95%.The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the business earned $1.38 earnings per share. As a group, equities analysts predict that Organon &amp; Co. will post 3.68 EPS for the current year.</p>
<div class="lb-trans"><p>Organon &amp; Co.（紐約證券交易所代碼：OGN - 獲取免費報告）最近在 11 月 10 日發佈了季度財報。該公司報告季度每股收益為 1.01 美元，超出市場共識預期的 0.93 美元，超出幅度為 0.08 美元。Organon &amp; Co.的股本回報率為 143.47%，淨利潤率為 7.95%。該公司在本季度的收入為 16 億美元，而市場共識預期為 15.7 億美元。在去年同期，該公司每股收益為 1.38 美元。整體來看，股票分析師預測 Organon &amp; Co.在當前年度的每股收益將達到 3.68 美元。</p>
</div><h2>Organon &amp; Co. Dividend Announcement</h2>
<div class="lb-trans"><h2>Organon &amp; Co.股息公告</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 20th. Organon &amp; Co.'s dividend payout ratio is currently 4.17%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度股息，將於 12 月 11 日支付。11 月 20 日的股東將獲得每股 0.02 美元的股息。這相當於年化股息 0.08 美元，股息收益率為 1.1%。該股息的除息日期為 11 月 20 日。Organon &amp; Co.目前的股息支付比率為 4.17%。</p>
</div><h2>About Organon &amp; Co.</h2>
<div class="lb-trans"><h2>關於 Organon &amp; Co.</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Organon &amp; Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.</p>
<div class="lb-trans"><p>Organon &amp; Co.是一家基於科學的全球製藥公司，通過一系列處方療法在女性健康、生物類似藥和成熟品牌領域開發和提供創新健康解決方案。該公司成立於 2020 年 3 月 11 日，總部位於新澤西州澤西市。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Organon &amp; Co.</li>
<li>Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>Asset Allocation Strategies in Volatile Markets</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Organon &amp; Co。</li>
<li>異常交易量的股票：如何實時找到異常交易量的股票</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的影響</li>
<li>如何一步一步購買便宜股票</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>動盪市場中的資產配置策略</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=OGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Organon &amp; Co.嗎？</h2>
</div><p>Before you consider Organon &amp; Co., you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Organon &amp; Co.之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Organon &amp; Co.並不在名單上。</p>
</div><p>While Organon &amp; Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Organon &amp; Co.目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

挪威銀行在 Organon & Co. $OGN 中建立了 1978 萬美元的頭寸